| P2093 | author name string | Jorge Frank | |
| | Pamela Poblete-Gutiérrez | |
| | Marko Siegesmund | |
| | Anne-Moniek van Tuyll van Serooskerken | |
| P2860 | cites work | Characterization of mutations in the CPO gene in British patients demonstrates absence of genotype-phenotype correlation and identifies relationship between hereditary coproporphyria and harderoporphyria | Q24533469 |
| | A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria | Q28282782 |
| | Characterization of the heme synthesis enzyme coproporphyrinogen oxidase (CPO) in zebrafish erythrogenesis | Q28312196 |
| | Identification of a founder mutation in the protoporphyrinogen oxidase gene in variegate porphyria patients from chile | Q31927593 |
| | The genetic bases of the porphyrias | Q33644315 |
| | Variegate porphyria: past, present and future | Q33644320 |
| | The little imitator--porphyria: a neuropsychiatric disorder | Q33735657 |
| | Early administration of heme arginate for acute porphyric attacks | Q34061438 |
| | Recovery from a variegate porphyria by a liver transplantation | Q34331539 |
| | Diagnosis and treatment of the acute porphyrias: an interdisciplinary challenge | Q34399869 |
| | Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. | Q34509663 |
| | Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement | Q34520894 |
| | Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria - an epidemiological investigation | Q35991567 |
| | Acute hepatic porphyria and hepatocellular carcinoma | Q36466461 |
| | Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden | Q39392641 |
| | montalcino, A zebrafish model for variegate porphyria | Q40081754 |
| | Porphyrias: animal models and prospects for cellular and gene therapy. | Q40433965 |
| | Review: molecular pathogenesis of hepatic acute porphyrias. | Q41294557 |
| | Variegate porphyria | Q41727534 |
| | A retrospective analysis of outcome of pregnancy in patients with acute porphyria | Q43010126 |
| | Combined liver and kidney transplantation in acute intermittent porphyria | Q43211557 |
| | Linkage disequilibrium analysis in a recently founded population: evaluation of the variegate porphyria founder in South African Afrikaners | Q43217326 |
| | Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria | Q43264943 |
| | Identification and characterization of HMBS gene mutations in Spanish patients with acute intermittent porphyria | Q43298236 |
| | Zinc mesoporphyrin represses induced hepatic 5-aminolevulinic acid synthase and reduces heme oxygenase activity in a mouse model of acute hepatic porphyria | Q43601208 |
| | Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. | Q43905234 |
| | A mouse model for South African (R59W) variegate porphyria: construction and initial characterization | Q43944281 |
| | Correction of the biochemical defect in porphobilinogen deaminase deficient cells by non-viral gene delivery | Q44577118 |
| | Treatment of an acute attack of porphyria during pregnancy | Q44685865 |
| | Liver transplantation as a cure for acute intermittent porphyria | Q44786720 |
| | The third case of Doss porphyria (delta-amino-levulinic acid dehydratase deficiency) in Germany | Q45012798 |
| | Refractory status epilepticus due to acute hepatic porphyria in a pregnant woman: induced abortion as the sole therapeutic option? | Q45094148 |
| | Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders | Q45384822 |
| | Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study. | Q46032688 |
| | Medical termination of pregnancy in acute intermittent porphyria | Q46973496 |
| | Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion | Q51760055 |
| | The hepatic porphyrias: experience with 105 cases | Q67875866 |
| | Instability of hematin used in the treatment of acute hepatic porphyria | Q69554140 |
| | Hepatocellular Carcinoma in Patients with Acute Intermittent Porphyria | Q70216270 |
| | Renal symptomatology in patients with acute intermittent porphyria. A population-based study | Q73210861 |
| | Acute Porphyria: Treatment with Heme | Q74359774 |
| | NEUROLOGICAL MANIFESTATIONS OF ACUTE INTERMITTENT PORPHYRIA | Q76644112 |
| | Unusual manifestation of acute hepatic porphyria in pregnancy | Q79397566 |
| | Porphyrias | Q83185413 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 593-605 | |
| P577 | publication date | 2010-10-01 | |
| P1433 | published in | Best Practice and Research: Clinical Gastroenterology | Q15754316 |
| P1476 | title | The acute hepatic porphyrias: current status and future challenges | |
| | The acute hepatic porphyrias: Current status and future challenges | |
| P478 | volume | 24 | |